Enanta Pharmaceuticals | ENTA - Net Income


Enanta Pharmaceuticals reported $-22.29M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 3.12B 610M Sep/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 1.54B 1.11B Sep/2026
Halozyme Therapeutics USD 247.05M 17.14M Sep/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD -784.8M 1.37B Sep/2026
Insmed USD -13.24M 150.32M Jun/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
J&J USD 210M 5.32B Sep/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD -28.48M 76.99M Sep/2026
Merck USD 5.07B 6.4B Sep/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD 3.24B 3.49B Sep/2026
PTC Therapeutics USD 83.5M 86.3M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sarepta Therapeutics USD -28.46M 23.57M Sep/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026